Predicting how high shares of Viking Therapeutics (traded under the ticker VKTX) can climb involves evaluating clinical trial milestones, pipeline potential in metabolic and weight-loss therapeutics, and competitive dynamics within the biotechnology sector. Wall Street equity research analysts tracking the clinical-stage biopharmaceutical company frequently issue ambitious twelve-month price targets based on the successful advancement of its proprietary drug candidates targeting obesity and non-alcoholic steatohepatitis. While bullish analyst projections suggest substantial upside potential if upcoming clinical readouts and regulatory approvals meet expectations, stock valuations in the biotech sector remain inherently volatile and sensitive to clinical trial outcomes.